Posted by Michael Wonder on 31 May 2021
Campaign launched for life-sustaining treatment access across Canada
31 May 2021 - Alpha-1 Canada publicly launched Access for Alphas today, a campaign aimed at raising the awareness of alfa-1 antitrypsin deficiency with provincial elected officials to approve an augmentation therapy category on the Canadian Blood Services Plasma Protein and Related Products Formulary for Canadians across the country with this progressive genetic disease.
“For decades alpha-1 patients have suffered silently without being able to access life-sustaining therapy. That ends today with the launch of Access for Alphas, which aims to finally get provinces to approve the addition of augmentation therapy within Canadian Blood Services, so that hundreds of Canadians can access this vital treatment,” began Angela Diano, Executive Director of Alpha-1 Canada.
